The Week in Review: US Charges Four China Pharmas with Price-Fixing

Four China vitamin C makers have been charged with price fixing in the US, but claim China’s government forced their collusion; China rapidly identified a new pathogen that caused death in 30% of all diagnosed cases; Jilin Jian Yisheng Pharma, a TCM drugmaker, completed a $177 million IPO in Shenzhen; First China Pharma signed a LOI to acquire a drug distributor in Shenzhen; Pharmaron will perform contract manufacturing for Isis Pharma; Shenogen Pharma will use CRO ShangPharma for development work on a novel cancer compound; Novo Nordisk received SFDA approval for a type 2 diabetes drug, Victoza®; Pfizer will move its antibacterials research operations from Connecticut to Shanghai; and SuperNova Diagnostics® found a China distribution partner in Kang Sheng Bao Bio-Technology. More details…. Stock Symbol: (SHE: 002566) (OTCBB: FCPG) (NSDQ: ISIS) (NYSE: SHP) (NYSE: NVO) (NYSE: PFE) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});